Vimarsana
Biggest News Aggregation in the World

Continued Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Continued Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Continued Development Today - Breaking & Trending Today

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation - Vimarsana News

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse. The pre-IND teleconference included representatives f

Source: yahoo.com
Maryland coalition call on attorney general and release environmental justice report - Vimarsana News

Maryland coalition call on attorney general and release environmental justice report

The citizen-led 3P Protect Perryman Peninsula coalition held a news conference Thursday in Annapolis where they released an environmental justice report focusing on the decades of environmental, social challenges and neglect in Perryman. The coalition plans to give the report, “Turning the Tide,” to Maryland Attorney General Anthony Brown in hopes he’ll investigate the continued development to ...

Source: yahoo.com
Bionomics : Statutory Accounts - Form 6-K -September 29, 2023 at 10:53 am EDT - Vimarsana News

Bionomics : Statutory Accounts - Form 6-K -September 29, 2023 at 10:53 am EDT

Statutory Accounts Director's Report In accordance with the Corporations Act 2001, the directors of...

Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis - Vimarsana News

Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial...

DCC : Final Results – 31 March 2023 | MarketScreener - Vimarsana News

DCC : Final Results – 31 March 2023 | MarketScreener

PRESS RELEASE 16 May 2023 ... | May 18, 2023